Plasma Xa inhibitory activities and plasma concentrations of norgestrel and ethinyloestradiol in women on oral contraceptive steroids. 1979

D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster

UI MeSH Term Description Entries
D009644 Norgestrel A synthetic progestational agent with actions similar to those of PROGESTERONE. This racemic or (+-)-form has about half the potency of the levo form (LEVONORGESTREL). Norgestrel is used as a contraceptive, ovulation inhibitor, and for the control of menstrual disorders and endometriosis. 18,19-Dinorpregn-4-en-20-yn-3-one, 13-ethyl-17-hydroxy-, (17alpha)-(+-)-,DL-Norgestrel,Neogest,Ovrette,Postinor,Wy-3707,DL Norgestrel,Wy 3707,Wy3707
D003276 Contraceptives, Oral Compounds, usually hormonal, taken orally in order to block ovulation and prevent the occurrence of pregnancy. The hormones are generally estrogen or progesterone or both. Low-Dose Oral Contraceptive,Oral Contraceptive,Oral Contraceptives,Oral Contraceptives, Low-Dose,Oral Contraceptives, Phasic,Contraceptive, Low-Dose Oral,Contraceptive, Oral,Contraceptives, Low-Dose Oral,Contraceptives, Phasic Oral,Low Dose Oral Contraceptive,Low-Dose Oral Contraceptives,Oral Contraceptive, Low-Dose,Oral Contraceptives, Low Dose,Phasic Oral Contraceptives
D003277 Contraceptives, Oral, Combined Fixed drug combinations administered orally for contraceptive purposes. Combined Oral Contraceptive,Contraceptive Agents, Female, Combined,Oral Contraceptives, Combined,Combined Oral Contraceptives,Contraceptive, Combined Oral,Contraceptives, Combined Oral,Oral Contraceptive, Combined
D003278 Contraceptives, Oral, Hormonal Oral contraceptives which owe their effectiveness to hormonal preparations. Hormonal Oral Contraceptive,Hormonal Oral Contraceptive Agent,Contraceptive Agents, Estrogen,Contraceptive Agents, Oral, Hormonal,Hormonal Oral Contraceptive Agents,Oral Contraceptive Agents, Hormonal,Oral Contraceptives, Hormonal,Contraceptive, Hormonal Oral,Contraceptives, Hormonal Oral,Estrogen Contraceptive Agents,Hormonal Oral Contraceptives,Oral Contraceptive, Hormonal
D004997 Ethinyl Estradiol A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES. 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-,Ethynyl Estradiol,Estinyl,Ethinyl Estradiol Hemihydrate,Ethinyl Estradiol, (8 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,17 alpha)-Isomer,Ethinyl Estradiol, (8 alpha,9 beta,13 alpha,14 beta)-Isomer,Ethinyl Estradiol, (9 beta,17 alpha)-Isomer,Ethinyl-Oestradiol Effik,Ethinylestradiol Jenapharm,Ethinyloestradiol,Lynoral,Microfollin,Microfollin Forte,Progynon C,Estradiol, Ethinyl,Estradiol, Ethynyl,Ethinyl Oestradiol Effik,Hemihydrate, Ethinyl Estradiol,Jenapharm, Ethinylestradiol
D005170 Factor X Storage-stable glycoprotein blood coagulation factor that can be activated to factor Xa by both the intrinsic and extrinsic pathways. A deficiency of factor X, sometimes called Stuart-Prower factor deficiency, may lead to a systemic coagulation disorder. Autoprothrombin III,Coagulation Factor X,Stuart Factor,Stuart-Prower Factor,Blood Coagulation Factor X,Factor 10,Factor Ten,Stuart Prower Factor,Factor X, Coagulation
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
June 1987, British journal of clinical pharmacology,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
January 2002, British journal of clinical pharmacology,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
May 1980, Journal of steroid biochemistry,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
January 1978, Contraception,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
September 1977, American journal of obstetrics and gynecology,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
April 1986, Contraception,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
July 1983, Contraception,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
July 1982, British journal of clinical pharmacology,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
January 1989, West African journal of medicine,
D J Back, and M Bates, and M W Burke, and A M Breckenridge, and F E Crawford, and M MacIver, and M L Orme, and P H Rowe, and E Smith, and S Webster
September 1977, Experientia,
Copied contents to your clipboard!